Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy. Cross-sectional Analyses of Baseline Data of the EUROCONDOR project by Santos, Ana Rita et al.
Syddansk Universitet
Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic
Retinopathy. Cross-sectional Analyses of Baseline Data of the EUROCONDOR project
Santos, Ana Rita; Ribeiro, Luisa; Bandello, Francesco; Lattanzio, Rosangela; Egan,
Catherine; Frydkjær-Olsen, Ulrik; García-Arumí, José; Gibson, Jonathan; Grauslund, Jakob;
Harding, Simon P; Lang, Gabriele E; Massin, Pascale; Midena, Edoardo; Scanlon, Peter;
Aldington Hnd, Stephen J; Simão, Sílvia; Schwartz, Christian; Ponsati, Berta; Porta,
Massimo; Costa, Miguel Ângelo; Hernández, Cristina; Cunha-Vaz, José; Simó, Rafael;
European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)
Published in:
Diabetes
DOI:
10.2337/db16-1453
Publication date:
2017
Document version
Peer reviewed version
Citation for pulished version (APA):
Santos, A. R., Ribeiro, L., Bandello, F., Lattanzio, R., Egan, C., Frydkjaer-Olsen, U., ... European Consortium for
the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2017). Functional and Structural Findings of
Neurodegeneration in Early Stages of Diabetic Retinopathy. Cross-sectional Analyses of Baseline Data of the
EUROCONDOR project. Diabetes, 66(9), 2503-2510. DOI: 10.2337/db16-1453
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
1 
 
Title: Functional and Structural Findings in Early Stages of Diabetic Retinopathy. Cross-
sectional analyses of the baseline data of the EUROCONDOR project.  
Short running title: Cross-sectional analyses of the baseline results of the 
EUROCONDOR project 
Ana Rita Santos MSc1, Luísa Ribeiro MD1, Francesco Bandello MD2, Rosangela Lattanzio 
MD2, Catherine Egan MD3, Ulrik Frydkjaer-Olsen PhD4, José García-Arumí MD5, Jonathan 
Gibson MD6, Jakob Grauslund DMSci4, Simon P Harding MD7, Gabriele E Lang MD8, Pascale 
Massin MD9, Edoardo Midena MD10, Peter Scanlon MD11, Steve Aldington HND11, Sílvia 
Simão BSc1, Christian Schwartz1, Berta Ponsati PhD12, Massimo Porta MD13, Miguel Ângelo 
Costa MSc1, Cristina Hernández MD14, José Cunha-Vaz MD1*, Rafael Simó MD14*. The 
European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) 
Affiliation: 
1. Association for Innovation and Biomedical Research on Light and Image (AIBILI). Coimbra, 
Portugal 
2. Department of Ophthalmology. University Vita-Salute. Scientific Institute San Raffaele. 
Milano, Italy 
3. Moorfields Eye Hospital NHS Foundation Trust, Institute of Ophthalmology/University 
College London. London, UK 
4. Department of Clinical Research, Research Unit of Ophthalmology, University of Southern 
Denmark. Denmark 
5. Department of Ophthalmology. Vall d’Hebron University Hospital. Barcelona, Spain. 
6. Department of Vision Sciences, Aston University. Birmingham, UK 
7. Department of Eye & Vision Science, Institute of Ageing and Chronic Disease, University of 
Liverpool. Liverpool, United Kingdom 
8. Department of Ophthalmology, University of Ulm. Ulm, Germany 
9. Department of Ophthalmology, Lariboisière Hospital. Paris, France 
10. Department of Ophthalmology, University of Padova. Padova, Italy 
11. Gloucestershire Hospitals NHS Foundation Trust. Cheltenham , UK 
12. BCN Peptides. Barcelona, Spain 
13. Department of Medical Sciences, University of Turin. Turin, Italy 
14. Diabetes and Metabolism Research Unit and CIBERDEM. Vall d’Hebron Research Institute. 
Barcelona, Spain 
Corresponding authors* 
José Cunha-Vaz 
Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, 
Portugal. 
Azinhaga de Santa Comba, Celas 
3000-548 Coimbra, Portugal 
e-mail: cunhavaz@aibili.pt 
 
Rafael Simó 
Diabetes and Metabolism Research Unit and CIBERDEM.  
Vall d’Hebron Research Institute.  
Pg. Vall d’Hebron 119-129, 08035 Barcelona, Spain 
e-mail: rafael.simo@vhir.org 
 
  
2 
 
Abstract  
The aim of this cross-sectional study is to evaluate the relationship between: a) the functional 
and structural measurements of neurodegeneration in initial stages of diabetic retinopathy (DR); 
b) the presence of neurodegeneration and early microvascular impairment. For this purpose 
baseline data of type 2 diabetic patients (n=449) enrolled in the EUROCONDOR study 
(NCT01726075) were analyzed. Functional studies were performed by multifocal ERG 
(mfERG) to evaluate neurodysfunction and structural measurements by Spectral Domain 
Optical-Coherence Tomography (SD-OCT) to evaluate neurodegeneration. The relationship 
between SD-OCT and mfERG was examined by superimposing the SD-OCT map of ganglion 
cell layer inner plexiform layer (GCL-IPL) over the central rings of mfERG. Among mfERG 
measurements, P1 amplitude was more sensitive than the implicit time (IT), and it was lower 
in patients with ETDRS 20-35 than in patients with ETDRS <20 (p=0.005). In 58% of cases, 
mfERG abnormalities were present in the absence of microangiopatic lesions in fundus 
photography. Regarding SD-OCT, GCL-IPL thickness was lower in diabetic patients than in 
control subjects but only 9% presented values below the normal range. Correspondence 
between SD-OCT thinning and mfERG abnormalities was shown in 67% of the eyes with 
ETDRS <20 and in 83% of the eyes with ETDRS 20-35. Notably, 32% of patients with ETDRS 
20-35 presented no abnormalities in mfERG or SD-OCT. We conclude that there is a link 
between mfERG and SD-OCT measurements which increases with the presence of 
microvascular impairment. However, in our particular study population (ETDRS ≤ 35) a 
significant proportion of patients had normal GC-IPL thickness and normal mfERG 
characteristics. These findings open up the hypothesis that neurodegeneration could play a role 
in the pathogenesis of DR in a large proportion, but not in all type 2 diabetic patients. 
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Diabetic retinopathy (DR) is the commonest complication of diabetes and remains the leading 
cause of blindness among working-age individuals in most developed countries (1). Since the 
global incidence of diabetes is set to rise dramatically from an estimated 382 million people in 
2013 to 592 million by 2030 (2), DR will become an even more serious problem in the coming 
years.      
Tight control of blood glucose levels and blood pressure are essential in preventing DR 
development or arresting its progression. However, current treatments for DR are targeted at 
advanced stages when laser photocoagulation, intravitreal injections of anti-VGF agents or 
corticosteroids and vitreoretinal surgery are implemented. All these treatments are invasive, 
expensive, require a retinal specialist and have a significant number of secondary effects. 
Therefore, new treatments for the early stages of DR are needed (3, 4).  
DR has been classically considered as a microvascular disease of the retina. However, growing 
evidence suggests that retinal neurodegeneration is an early event in the pathogenesis of DR, 
which could participate in the development of microvascular abnormalities (5-8). For this 
reason, it is reasonable to hypothesize that therapeutic strategies based on neuroprotection may 
be effective not only in preventing or arresting retinal neurodegeneration, but also in preventing 
the development and progression of the early stages of DR in terms of microvascular 
impairment (3, 8). This opens up the possibility of developing topical therapy in the early stages 
of DR, when currently established therapies such as laser photocoagulation or intravitreal 
injections of corticosteroids or anti-VEGF agents are inappropriate (8-10). EUROCONDOR 
(European Consortium for the Early Treatment of Diabetic Retinopathy) has been created in 
order to implement a large clinical trial (NCT01726075) using eye drops containing 
brimonidine or somatostatin (two previously demonstrated neuroprotective agents), in the early 
stages of diabetic retinal disease.  
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Multifocal electroretinography (mfERG) and spectral domain optical coherence tomography 
(SD-OCT) have both been employed in clinical studies to measure neurodysfunction and 
neurodegeneration. The mfERG has been shown to sensitively detect the presence of 
neuroretinal dysfunction in type 1 diabetic patients even without any detected blood-retinal 
barrier leakage measured by vitreous fluorometry (11). In addition, and more importantly, 
several authors have found that an increase of the implicit time (IT) in mfERG is a predictor 
for the development of visible vascular abnormalities over 1-year (12, 13), and 3-year periods 
(14). However, mfERG is cumbersome for the patient and time-consuming and, therefore, is 
only used in the setting of clinical trials. SD-OCT provides anatomical and structural 
information and is widely available, easy to perform and comfortable for the patients. However 
there is little information regarding the relationship between mfERG and SD-OCT and the 
presence of early microvascular impairment.  
On this basis, the aim of the present work was to analyze the relationship between baseline 
mfERG characteristics and structural abnormalities assessed by SD-OCT, taking into account 
the degree of microvascular abnormalities in the early stages of DR.  
Research Design and Methods 
Study Subjects 
The data for this cross-sectional study derived from the 449 type 2 diabetic patients with either 
no visible DR (ETDRS level <20) or only early stages of DR (ETDRS level 20-35) enrolled in 
the prospective, multicenter and randomized clinical trial EUROCONDOR (NCT01726075). 
This clinical trial was performed by 11 European ophthalmology clinical research centres of 
the European Consortium for the Early Treatment of Diabetic Retinopathy and funded by the 
European Commission 7th Framework Programme (Grant Agreement N: 278040).  
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In addition to ETDRS level ≤35, the inclusion criteria were duration of diabetes for at least 5 
years and age between 45-75 years. Exclusion criteria included previous laser 
photocoagulation, retinal degeneration-inducing diseases (i.e. glaucoma) and refractive error 
greater than or equal to +/-5 dioptre. Eyes with hazy ocular media or inadequate pupil dilatation 
that prevented good quality fundus photography were excluded. Patients with renal failure 
(creatinine > 123.76 µmol/L) or A1C > 10% (86 mmol/mol) in the previous 6 months were also 
excluded.  
The study adhered to the tenets of the Declaration of Helsinki and was approved by the review 
boards of each participant country. Written informed consent was obtained from all patients 
before performing any procedures. 
Each patient underwent a comprehensive ophthalmic examination, including a review of the 
medical history, best corrected visual acuity (BCVA) using ETDRS protocol, slit-lamp 
biomicrospcopy, intraocular pressure measurement with Goldmann applanation tonometry, 
gonioscopy and dilated fundoscopic examination, and fasting blood sampling for blood count 
and biochemistry analysis. In addition, standardized 7 field color fundus photography (CFP), 
SD-OCT and mfERG were performed in all patients. These 3 examinations took place within 
the timeframe of one month and their outputs were graded by a centralized reading center 
(AIBILI CORC – Coimbra Ophthalmology Reading Center). Only one eye from each patient 
was included in the study. If both eyes met the inclusion criteria, one of the eyes was chosen 
randomly.  
Grading data were analyzed in two groups according to ETDRS severity scale: patients with 
ETDRS level <20 (without microaneurysms), and patients with ETDRS level 20-35 (mild 
nonproliferative DR).  
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Multifocal ERG Recording and Analysis  
The mfERGs were recorded in the study eye using the RETI-port/scan 21 (Roland Consult, 
Berlin, Germany) visual electrophysiology system. Stimulation and recording of the mfERG 
responses were performed according to the International Society for Clinical Electrophysiology 
of Vision (ISCEV) guidelines (15, 16). After full dilation of the pupil with 1% tropicamide and 
2,5% phenylephrine and topical anesthesia, a DTL-plus electrode was placed in the lower 
conjuntival fornix, a reference skin electrode was placed near the orbital rim and a ground skin 
electrode was attached in the forehead. The fellow eye was occluded and impedances were 
checked. The patient had to fixate a large red cross in the stimulation monitor and the fixation 
was controlled using a fundus camera and illumination with infrared light. The stimulus array 
consisted of 103 hexagons displayed at a 60-Hz frame rate and was centered on the fovea 
covering a visual field of 30º. The luminance of each hexagon was independently alternated 
between black (<2cd/m2 of luminance) and white (200cd/m2 of luminance) according to a 
pseudorandom binary m-sequence. Each recording was taken in 12 cycles of approximately 47 
seconds each with an artefact rejection level of 10%. Exams on the baseline visit were rejected 
when they presented any of the following: (1) ‘eccentric fixation’; (2) ‘unsteady fixation’; and 
‘too much noise compromising the waveform’. Sixty-four (64) exams had to be retaken. After 
the request, all exams were of sufficient quality to be included in the study cohort. 
Data corresponding to P1 amplitude and IT of 103 hexagons, organized in 6 concentric rings 
(Figure 1A) obtained in type 2 diabetic patients were compared with a normative database (n= 
111 healthy eyes from 76 non-diabetic age-matched controls) which was also generated in the 
setting of the EUROCONDOR project (17). Healthy volunteers recruited for the mfERG 
normative database were checked for diabetes by a revision of the medical history with recent 
blood analysis data. In addition, patients with any known ophthalmic disease were excluded 
from the study. 
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Figure 1 A and B 
Figure 1: A. Diagram of the stimulus array used to elicit the multifocal ERGs. Stimulus 
consisted of 103 hexagons, organized in 6 concentric rings, scaled (not represented) to elicit 
similar amplitudes at all locations. B. Superimposition of the mfERG stimulus array and the 
SD-OCT GCL+IPL elliptical annulus grid (blue) on a fundus image, centered on the fovea. The 
green-contoured hexagon represents the central mfERG hexagon, and the two grey circles 
represent the 10º and 20º of the mfERG grid. 
 
OCT Imaging and Analysis 
Spectral Domain OCT (SD-OCT) images were acquired by CIRRUS HD-OCT (Zeiss Meditec), 
henceforth designated as CIRRUS, or by Topcon 3D-OCT 2000 (Topcon Corporation), 
henceforth designated as Topcon, depending on the equipment available at each site, according 
to standardized acquisition protocols. A total of 284 patients underwent  CIRRUS HD-OCT 
imaging (117 patients with ETDRS level <20 and 167 patients with ETDRS level 20-35), while 
165 patients underwent Topcon 3D-OCT 2000 imaging (76 patients with ETDRS level <20 and 
89 patients with ETDRS level 20-35). OCT scans were accepted upon confirmation of good 
quality and the absence of segmentation errors that compromised quantitative analysis. Thirteen 
exams had to be retaken. After the request all exams were of sufficient quality to be included 
in the study cohort. 
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Macular retinal thickness and macular GCL-IPL thickness were obtained from Macular Cube 
512x128 acquisition of CIRRUS equipment and from 3D Macula 6mm x 6mm acquisition of 
Topcon, both acquired centered on fovea.  Peripapillary RNFL thickness was obtained from 
CIRRUS using Optic Disc Cube acquisition and from Topcon using the 3D Disc 6.0mm x 
6.0mm acquisition. 
GCL-IPL and RNFL thicknesses obtained in type 2 diabetic patients were compared with 
normative databases of the respective equipment manufacturers. The normal RNFL values of 
the CIRRUS HD-OCT were calculated by determining the average value for a 62.5 years old 
person (the mean age of the population assessed with that equipment). 
To account for differences between Topcon and CIRRUS equipment, mean values of macular 
thickness, macular GCL-IPL thickness and RNFL thickness at the optic disc were tested for 
each equipment. In order to address the differences, a conversion factor (mean CIRRUS value 
divided by mean Topcon value) was then multiplied for Topcon measurements (given that 
Topcon was used at only four sites). Conversions factors were 1.11, 1.20, and 0.93 for macular 
retinal thickness, macular GCL-IPL thickness, and RNFL thickness at the optic disc, 
respectively (18).  
Topographical coincidence between mfERG abnormalities and SD-OCT impairment 
By superimposing the OCT map of GCL-IPL over the mfERG hexagonal pattern (Figure 1B), 
we analysed the mfERG central rings: Ring 1, Ring 2 and Ring 3 (Figure 1A, red-delimited 
area). The P1 amplitude and IT were analyzed by the number of abnormal hexagons (an altered 
hexagon was defined as a hexagon with a z-score ≥2 for IT and ≤-2 for amplitude). The 
relationship between the presence of abnormal hexagons and thinning of the GCL-IPL and 
RNFL layers was examined. 
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An eye with a central mfERG abnormality was defined as having at least one abnormal hexagon 
in any of the three central rings (Figure 1). 
 
Statistical Analysis 
Descriptive statistics were calculated for all variables. Differences between normal values of 
mfERG amplitude and IT were inferred with one way analysis of variance (ANOVA). The 
correlation between mfERG or GCL-IPL/RNFL thickness parameters and age, diabetes 
duration and A1C was explored with multivariate logistic regression. The relationship between 
abnormalities in central mfERG parameters and thinning of GCL-IPL and/or RNFL was 
explored with chi-square test. Multiple comparison corrections (Bonferroni) were performed 
where indicated in the results section. Statistical analysis was performed with Stata 12.1 
(StataCorp LP, College Station, TX, USA) and significance was set at 0.05. 
 
Results 
General description 
Four hundred and forty-nine type 2 diabetic patients were included in this baseline analysis of 
the EUROCONDOR cohort. The main clinical characteristics of the patients, taking into 
account the ETDRS levels are displayed in Table 1.  
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Table 1. Demographic characteristics of study patients 
 Total 
N=449 
ETDRS <20 
(n=193) 
ETDRS 20-35 
(n=256) 
p* 
Age (years) 62.82±6.70 64.32±6.40 61.70±6.80 <0.001 
Gender (% males) 65.9 70.5 62.5 n.s 
Diabetes duration (years) 11.66±5.60 10.57±5.10 12.48±5.90 <0.001 
Fasting blood glucose  (mg/ml) 
(mmol/L) 
144±52 
7.99±2.89 
137±46 
7.60±2.55 
149±55 
8.27±3.05 
0.018 
A1C (%) 
 (mmol/mol) 
7.16±1.00  
(55±10.9) 
7.01±0.90 
(53±9.9) 
7.28±1.10 
(56±11.5) 
0.006 
Hypertension (%) 73.3 73.1 73.4 n.s 
Dyslipidemia (%) 70.8 74.1 68.4 n.s 
Current smokers (%) 13.4 13.5 13.3 n.s 
Microalbuminuria (%) 12.9 11.7 13.7 n.s 
Cardiovascular disease (%) 20.3 22.3 18.8 n.s 
BCVA letters Score 86.14±5.10 85.78±5.40 86.42±4.80 n.s 
* p value between ETDRS <20 and ETDRS 20-35 
 
mfERG abnormalities  
Diabetic patients presented a significantly delayed IT from rings 3-6 (p<0.001) in comparison 
with age-matched non-diabetic control group (Table 2). We found no influence of ETDRS 
levels on P1 IT. Furthermore, the mean IT (ms) of the 6 rings was similar in type 2 diabetic 
patients with ETDRS level <20 or ETDRS level 20-35 (36.66 ±1.76 vs. 36.64±1.76; p=n.s). 
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Table 2. Values of P1 implicit time and amplitude (mean±SD) of the six concentric rings in 
healthy controls and type 2 diabetic patients. 
  
Ring 
Healthy 
controls 
(n=76) 
ETDRS <20  
(n=193) 
ETDRS 20-35  
(n= 256) 
 
P* 
 1 42.0±3.5 42.1±4.7 42.1±4.7 0.63 
 2 36.0±2.0 36.6±2.9 36.6±2.8 0.08 
Implicit Time 3 34.2±1.8† 35.6±2.0 35.6±1.7 <0.001 
(ms) 4 33.5±1.8 † 35.0±1.7 35.1±1.7 <0.001 
 5 33.4±1.7 † 35.0±1.7 35.1±1.9 <0.001 
 6 33.8±1.8 † 35.3±1.9 35.4±1.7 <0.001 
 1 128.9±26.4 † 118.4±40.1 111.5±35.8 <0.001 
 2 70.2±13.3† 56.3±16.1‡ 52.6±14.6§ <0.001 
Amplitude 3 46.8±8.3† 37.7±10.7‡ 34.5±9.1§ <0.001 
(nV/deg2) 4 32.6±5.7† 26.7±8.1‡ 24.4±6.8§ <0.001 
 5 25.0±4.7† 20.5±6.4‡ 18.8±5.5§ <0.001 
 6 20.3±4.0† 16.3±5.4 15.3±5 <0.001 
* p value from ANOVA 
†
 significantly different from ETDRS <20 and ETDRS 20-35 
‡
 significantly different from Healthy controls and ETDRS 20-35 
§ significantly different from Healthy controls and ETDRS <20 
 
The mean values of P1 amplitude were significantly lower in diabetic patients than in control 
group in all rings (all p<0.001), and the differences were even higher in patients with ETDRS 
level 20-35 than in patients without microangiopathic abnormalities (ETDRS <20) (Table 2). 
Thus, the mean amplitude (nV/deg2) was significantly higher in type 2 diabetic patients with 
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ETDRS <20 in comparison with those with ETDRS 20-35 (45.96 ± 12.29 vs. 42.77 ± 11.29; 
p=0.006). 
 The difference in P1 amplitude between central and peripheral retina (ring 1-ring 6) was 
significantly reduced in type 2 diabetic patients in comparison with non-diabetic subjects 
(99±35 nV/deg2 vs. 109±26 nV/deg2 ; p<0.001).  
Age was correlated with P1 IT (r=0.206; p<0.001) and no relationship was found between P1 
IT or amplitude with diabetes duration or A1C levels. 
Finally, the 58% of diabetic patients with ETDRS <20 presented abnormalities in central 
mfERG, and this percentage increase to 66% in diabetic patients with ETDRS 20-35 (p=0.07).  
SD-OCT abnormalities 
The average thickness of the macular GCL-IPL complex and the average thickness of the 
peripapillary RNFL were analyzed in the two DR study groups (ETDRS <20 and ETDRS 20-
35) and compared with the normal thickness values given by the normative databases provided 
by the equipment manufacturers. The homogenized results obtained after applying the 
conversion factors previously mentioned are displayed in Table 3.  
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Table 3. SD-OCT abnormalities by DR severity level 
 Normal Values 
N=282 
ETDRS <20 
N=193 
ETDRS 20-35 
N=256 
All patients 
N=449 
 
GCL-IPL (μm) 
 
82.1±6.2 
 
78.6±7.3* 
 
79.7±7.7* 
 
79.4±7.3† 
 
 
RNFL (μm) 
 
89.8±8.5 
 
88.6±10.3 
 
89.9±9.8 
 
89.1±9.7 
* Significantly different from Normal values on an independent samples t-test for p<0.025 (bonferroni 
correction for multiple comparisons) 
† Significantly different from Normal values on an independent samples t-test for p<0.05. 
Data are mean±SD 
 
The average GCL-IPL thickness was significantly lower in diabetic eyes when compared to the 
normal population (79.4±7.3 µm vs. 82.1±6.2 µm; p<0.001); but there was no difference among 
diabetics with different ETDRS levels (Table 3; p=n.s.). Conversely, average RNFL at the optic 
disc presented no significant differences between diabetic eyes and the normal population 
(89.1±9.7 µm vs. 89.8±8.5 µm; p=n.s). A total of 41 type 2 diabetic patients (9.1%) presented 
values of GCL-IPL or RNFL below the normal range.  
We found that type 2 diabetic patients with ETDRS 20-35 presented values of GC-IPL thickness 
higher than patients with ETDRS 10 (p=0.018). However, when the crude data were corrected 
taking into account total retinal thickness no relationship between GCL-IPL thickness and 
ETDRS levels was found. 
Age was negatively correlated with the average thicknesses of both GCL-IPL (r=-0.27; 
p<0.001) and RNFL (r=-0.17; p<0.001). However, no correlations were found between GCL-
IPL or RNFL thickness and diabetes duration or HbA1C  levels. 
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Relationship between SD-OCT and mfERG 
In the 193 eyes classified as having ETDRS level <20 (with no apparent microvascular 
abnormalities), central mfERG abnormalities of amplitude or IT were present in 58% of eyes 
and there was a decrease below the normal values of GCL-IPL or RNFL layers thickness in 
only 9% of the eyes. Similarly, eyes with ETDRS levels 20-35 (with microvascular changes) 
(n=256) showed central mfERG abnormalities of amplitude or IT in 66% of the cases and 
thinning of GCL-IPL or RNFL in 9%. 
The relationship between abnormalities in central mfERG parameters and thinning of GCL-IPL 
and/or RNFL is displayed in Table 4. In diabetic patients with ETDRS <20, 67% of the cases 
with GCL-IPL or RNFL thinning also presented mfERG abnormalities. However, in patients 
with ETDRS 20-35, 83% of the cases with GCL-IPL or RNFL thinning also presented mfERG 
abnormalities (p=0.07). 
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Table 4.  Correspondence between abnormalities in central mfERG and SD-OCT parameters. 
 All patients (n=449)  
 Normal mfERG 
N (%) 
Abnormal mfERG 
N (%) 
Normal SD-OCT, n (%) 160 (35.6) 248 (55.2) 
Abnormal SD-OCT, n (%) 10 (2.2) 31 (6.9) 
 p= 0.06 
                            ETDRS <20 (n=193) 
Normal SD-OCT, n (%) 76 (39.4) 99 (51.3) 
Abnormal SD-OCT, n (%) 6 (3.1) 12 (6.2) 
   
p= 0.41 
                           ETDRS 20-35 (n=256) 
Normal SD-OCT, n (%) 84 (32.8) 149 (58.2) 
Abnormal SD-OCT, n (%) 4 (1.6) 19 (7.4) 
  
 p= 0.07 
 
Relationship between measurements related to neurodegeneration and early 
microvascular impairment 
The relationship between the measurements related to neurodysfunction and/or 
neurodegeneration according to ETDRS levels are shown in Table 5. We found that 61% of 
diabetic patients with ETDRS <20 presented neurodysfunction/neurodegeneration and this 
proportion increased to 68% in patients with ETDRS 20-35 (Chi square: p=0.13). Therefore, 
neurodegeneration/neurodysfunction abnormalities did not significantly increase in presence of 
microvascular abnormalities but, as previously mentioned, this latter condition favored the 
clustering between mfERG and SD-OCT.  
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Table 5. Relationship between the measurements related to neurodysfunction and/or 
neurodegeneration according to ETDRS levels 
 
 No Microangiopathy 
ETDRS <20 
N=193 
Microangiopathy 
ETDRS 20-35 
N=256 
 No NRD NRD  No NRD NRD  
N (%) 75 (39) 118 (61)  82 (32) 174 (68)  
Age (years) 63.1±6.7 65.1±6.0 0.04 59.7±7.5 62.6±6.1 0.003 
BMI (Kg/m2) 30 31 ns 30 30 ns 
Diabetes duration (years) 11±5.5 10.3±4.8 ns 11.8±4.8 12.8±6.3 ns 
Fasting blood glucose (mg/dL) 
(mmol/L)  
129±44 
7.16±2.44 
142±47 
7.88±2.61 
0.07 148±56 
8.21±3.11 
149±55 
8.27±3.05 
ns 
HbA1c (%) 
(mmol/mol) 
7.05±0.79 
54 ± 
6.98±0.96 
53 ± 
ns 7.16±0.98 
55 ± 
7.32±1.08 
56 ± 
ns 
Mean IT (ms) 36.16±1.41 36.96±1.88 0.001 35.93±1.41 36.98±1.81 <0.001 
Mean A (nV/deg2) 51.35±11.11 42.56±12.89 0.012 48.61±9.00 40.12±11.22 <0.001 
GCL-IPL (μm) 80.47±5.92 77.39±7.77 0.004 82.09±6.77 78.66±7.90 0.001 
RNFL (μm) 90.70±9.17 87.35±9.67 0.018 92.18±8.31 88.22±10.28 0.003 
NRD: neurodysfunction and/or neurodegeneration 
 
It should be noted that 82 out of 256 patients with ETDRS 20-35 (32%) did not present any 
abnormalities in mfERG or SD-OCT examinations, thus suggesting the presence of primarily a 
microvascular or a microangiopathic phenotype. On the other hand 118 out of 193 patients 
(61%) without visible microvascular lesions (ETDRS<20) presented abnormalities related to 
neurodegeneration assessed by either mfERG (58%) or SD-OCT (9%), thus suggesting a 
neurodysfunctional or neurodegegenerative phenotype.  
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Discussion 
The EUROCONDOR study was designed to test the potential role of two different 
neuroprotective agents in arresting the progression of retinal neurodegeneration in the diabetic 
retina. The major functional test chosen to identify and follow neurodegeneration was mfERG 
and structural abnormalities were evaluated by SD-OCT. In this report, the baseline data have 
been evaluated in order to study the relationship between neurodegeneration assessed by 
mfERG (functional abnormalities) and SD-OCT (structural damage), as well as their 
relationship with the absence (ETDRS level <20) or presence (ETDRS levels 20-35) of early 
microvascular retinal impairment.  
Multifocal ERG is a highly sensitive method which allows for an objective and quantitative 
measurement of retinal function. When this technique is performed following a well-defined 
protocol by trained examiners, it offers reliable results, and may be particularly valuable for 
evaluating retinal neuron impairment. The baseline data collected from EUROCONDOR 
participants showed alterations of the mfERG in almost 60% of type 2 diabetic patients with no 
apparent fundus abnormalities (ETDRS level <20). These findings are in agreement with 
previous studies (11-14), and support the concept that functional impairment related to 
neurodegeneration is an early event in the diabetic retina. However, in 34% of type 2 diabetic 
patients with early microvascular impairment (ETDRS 20-35) mfERG abnormalities were not 
found. Therefore, it seems that in some type 2 diabetic patients, retinal neurodegeneration does 
not appear to play an essential role in the development of DR, at least when assessed by mfERG. 
The most widely used mfERG parameter in the setting of diabetes has been the P1 IT because 
of its lower variability in comparison to P1 amplitude. However, our results provide evidence 
that P1 amplitude, rather than IT, is the most sensitive parameter. We found a decrease of P1 
amplitude from the central to the peripheral retina (from ring 1 to ring 6) in both type 2 diabetic 
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patients and healthy controls. Our results agree with previous studies performed in Indian (19) 
and Japanese (20) normal subjects. The geographical distribution of cones (higher in the central 
retina and lower in the periphery) supports these findings (21, 22). Our results suggest that the 
difference in P1 amplitude from the central to the peripheral retina could be a useful parameter 
for monitoring the neurodegenerative process, but further studies to examine this issue are 
needed.   
One important issue to be considered when analyzing mfERG is the fluctuations of the results 
that could occur depending on the glycemic excursions. In the present study, patients with poor 
glycemic control (HbA1c >10%) were excluded, the mean of fasting glucose was 7.99 mmol/L 
± SD 2.89, HbA1c was 7.1% ± SD 1.0 (55 mmol/mol ± SD 10.9) and, more importantly we did 
not observe any relationship between fasting glycemia or HbA1c levels with mfERG 
abnormalities. For all these reasons, a potential influence of glycemic fluctuations on mfERG 
seems very unlikely. 
The most important structural damage of the retina detected by SD-OCT was a thinning of the 
GCL-IPL and RNFL layers, although in far fewer number of eyes/patients in comparison with 
mfERG abnormalities. However, mfERG abnormalities were absent in around 1/3 of patients 
with ETDRS level <20 in whom GCL-IPL or RNFL thickness were below the normal range. In 
this regard, it should be noted that mfERG is a measurement of cone photoreceptor and bipolar 
cell function (22), and may not represent inner retinal defects. Therefore, the observed 
dissociation between the two tests is not surprising. In addition, whereas the thinning of the 
neuroretina assessed by SD-OCT reflects neural loss, mfERG abnormalities could only be the 
consequence of neurodysfunction due to glial activation. This finding supports the 
complementarity of using both examinations when neurodysfunction/neurodegeneration is 
being assessed. One result that merits to be commented on is the absence of further GCL-IPL 
or RNFL thickness reduction when microangiopathy was detected, whereas P1 amplitude was 
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significantly reduced. In fact, an increase of GCL-IPL thickness was detected in patients with 
ETDRS 20-35 in comparison with patients with ETDRS <20. This could be attributed to the 
increased sensitivity of functional mfERG rather than structural SD-OCT abnormalities when 
assessing the neurodegenerative process. However, it is also possible that vascular leakage 
predominant in the Inner Nuclear layers (INL) in the initial stages of diabetic retinal disease 
leads to an increase in thickness of the retina, acting as a confounding factor. In a recent study, 
where a large cohort of diabetic eyes with non-proliferative retinopathy was followed for one 
year, thinning of GCL-IPL and RNFL was also found. But this increase in thinning was masked 
by the presence of retinal edema resulting from leakage from the retinal vessels and increase in 
the retinal extracellular space extending to the inner retinal layers (23). In this regard, in our 
study when the GCL-IPL thickness was corrected by taking into account total retinal thickness, 
the inverse relationship between GCL-IPL thickness and progression from ETDRS <20 to 
ETDRS 20-35 disappeared.       
Both mfERG and SD-OCT abnormalities were related to age. This finding was expected due to 
the direct relationship between the neurodegenerative process and age. The lack of association 
between mfERG and SD-OCT measurements of neurodegeneration and A1C could be 
attributed to the well-established concept that A1C levels taken at a certain point in time do not 
necessarily represent the previous history of metabolic control of the patient and, therefore, 
biomarkers of long-term glycation might be more informative than A1C levels. In addition, the 
excellent control of blood glucose levels in this cohort (mean A1C = 7.16% [55.2 mmol/mol] 
and only 30% patients over 7.5% [58.5 mmol/mol]) could also have contributed to this result.   
Little is known regarding the relationship between functional and structural abnormalities in 
the setting of diabetes-induced retinal neurodegeneration. In the present study we have found 
an impairment of the retinal function in the initial stages of retinal disease in type 2 diabetic 
patients with a good correspondence between central mfERG changes (3 central rings) and SD-
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OCT structural damage (thinning of GCL-IPL and RNFL layers), which increased with the 
progression of DR.  
It is worth mentioning that 32% of the patients with visible microvascular disease in color 
fundus photography (ETDRS 20-35) did not present any functional or structural abnormality 
related to neurodegeneration. This finding suggests the presence of a significant proportion of 
patients with a primarily microvascular or microangiopathic phenotype, in which the role of 
neurodegeneration remains to be elucidated. On the other hand 61% of the patients without 
visible microvascular disease (ETDRS<20) presented abnormalities related to 
neurodegeneration assessed by either mfERG or SD-OCT, thus suggesting the presence of a 
neurodysfucntional or neurodegenerative phenotype. Prospective follow up will determine 
whether this phenotype will be more prone to develop microvascular disease than in those 
patients without neurodegenerative abnormalities. The identification of these two phenotypes 
is an important issue because of its therapeutic implications, particularly when analyzing the 
potential effect of neuroprotective agents.  
In conclusion, functional abnormalities can be detected by mfERG in almost 60% of type 2 
diabetic patients with no apparent fundus abnormalities and these changes antedate the 
structural damage measured by SD-OCT. However, this is not a universal pattern and in a 
significant proportion of type 2 diabetic patients the development of microvascular disease is 
not preceded by any abnormality in neurodegeneration measurements used in this study (SD-
OCT and mfERG). Overall our findings open up the hypothesis that neurodegeneration could 
play a role in the pathogenesis of DR in a large proportion, but not in all type 2 diabetic patients.  
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Supplemental Material 
mfERG standardization 
Consistency of outcomes across multiple testing site was ensured through appropriate training 
and consistent monitoring of mfERG outcomes to maintain quality assurance standards. In 
order to ensure appropriate quality of participation an acquisition protocol was created and all 
clinical sites used the same equipment (RETI-port/scan21 – Roland Consult) set up with fixed 
acquisition parameters. At least one technician from all 11 sites received specialized training at 
Coimbra Ophthalmology Reading Centre to learn the acquisition protocol and to ensure 
consistency of the examination technique. In addition, all sites received individualized on-site 
refresher training following specialized training. Before acquiring any EUROCONDOR study 
exams, each technician performed four mfERG examinations (four eyes) according to the 
acquisition protocol that was reviewed by CORC to ensure quality exams and certify the 
technicians. 
 
 
 
